Results 1 to 10 of about 399,367 (396)

Chronic Myeloid Leukemia in 2020

HemaSphere, 2020
New insights have emerged from maturing long-term academic and commercial clinical trials regarding optimum management of chronic myeloid leukemia (CML).
R. Hehlmann
semanticscholar   +4 more sources

Chronic Myeloid Leukemia

Rare Diseases, 2020
Chronic myelogenous leukemia (CML) is a chronic clonal myeloproliferative disease characterized by left leukocytosis, splenomegaly, and the presence of the Philadelphia (Ph) chromosome, which results from the reciprocal and balanced translocation between
Letícia Antunes Muniz Ferreira
semanticscholar   +6 more sources

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

Haematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni, Mario Mauri, Deborah D’Aliberti, Caterina Mezzatesta, Ilaria Crespiatico, Miriam Nava, Diletta Fontana, Nitesh Sharma, Wendy Parker, Andreas Schreiber, David Yeung, Alessandra Pirola, Sara Readelli, Luca Massimino, Paul Wang, Praveen Khandelwal, Stefania Citterio, Michela Viltadi, Silvia Bombelli, Roberta Rigolio, Roberto Perego, Jacqueline Boultwood, Alessandro Morotti, Giuseppe Saglio, Dong-Wook Kim, Susan Branford, Carlo Gambacorti-Passerini, Rocco Piazza   +27 more
doaj   +2 more sources

Chronic Myeloid Leukemia [PDF]

Hematology, 2003
AbstractChronic myeloid leukemia (CML) was the first human malignancy to be associated with a specific genetic lesion, the Philadelphia chromosome, harboring the BCR-ABL oncogene. Since then, it has become a paradigm for the discovery of molecular mechanisms and targeted therapeutic approaches in the field of hematologic neoplasias. The past 5 years or
Junia V. Melo, Timothy P. Hughes, Jane F. Apperley   +2 more
  +7 more sources

Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers

Haematologica, 2021
Cancer treatment is constantly evolving from a one-size-fits-all towards bespoke approaches for each patient. In certain solid cancers, including breast and lung, tumor genome profiling has been incorporated into therapeutic decision-making. For chronic
Vaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P. Hughes, Susan Branford, S. Tiong Ong   +4 more
doaj   +1 more source

Up-regulation of SNHG5 Expression Level in Patients with Chronic Myeloid Leukemia Compared with Normal Individuals [PDF]

مجله دانشکده پزشکی اصفهان, 2022
Background: Chronic myeloid leukemia is a type of myeloproliferative malignancy that is associated with translocation between chromosomes 9 and 22 and accounts for approximately 15% of all leukemia.
Zahra Shahpouri-Arani, Mohamad Reza Hajari, Javad Mohammadi-Asl, Najmaldin Saki   +3 more
doaj   +1 more source

Priapism as the first symptom of chronic myeloid leukemia: literature review and own clinical case report

Онкогематология, 2022
Chronic myeloid leukemia is a ph-positive myeloproliferative disease, which is usually manifested by hyperleukocytosis and massive splenomegaly. Chronic myeloid leukemia is rare in childhood and adolescence, it accounts for 2 to 3 % of all leukemias ...
T. Yu. Pavlova, T. T. Valiev
doaj   +1 more source

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Leukemia, 2021
In the ENESTnd study, with ≥10 years follow-up in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase, nilotinib demonstrated higher cumulative molecular response rates, lower rates of disease progression and CML-related death ...
H. Kantarjian, T. Hughes, R. Larson, Dong-Wook Kim, S. Issaragrisil, P. le Coutre, G. Étienne, C. Boquimpani, R. Pasquini, R. Clark, V. Dubruille, I. Flinn, S. Kyrcz‐Krzemień, E. Mędraś, M. Zanichelli, I. Bendit, S. Cacciatore, Ksenia Titorenko, P. Aimone, G. Saglio, A. Hochhaus   +20 more
semanticscholar   +1 more source

T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]

Romanian Journal of Medical Practice, 2019
Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene, Ana Maria Vlădăreanu, Horia Bumbea, Ion Dumitru   +3 more
doaj   +1 more source

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

Leukemia, 2021
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly impacted by tyrosine kinase inhibitors (TKIs).
Y. Hsieh, K. Kirschner, M. Copland
semanticscholar   +1 more source